The Children's Oncology Group phase III AALL1231 clinical trial studied outcomes in children and young adults with T-ALL/T-LL who were randomly assigned to a modified augmented Berlin-Frankfurt-Münster (BFM) chemotherapy regimen with or without bortezomib. What kind of agent is bortezomib?
